TARSUS PHARMAC. DL-,0001

Tarsus reported Q2 2026 net product revenues for XDEMVY of $173.9 million (+69% year over year) and raised its full-year guidance for XDEMVY to $685–705 million. The group recorded a net loss of $18.6 million; gross margin stayed improved at around 93%, while R&D and SG&A expenses rose significantly due to trial costs and marketing spend. Tarsus completed the acquisition of Alkeus Pharmaceuticals, priced a private placement of $125 million and appointed Neera Clase as interim chief commercial officer; cash and cash equivalents stood at $449.7 million. » Plus sur de.investing.com

Tarsus has agreed to acquire Alkeus for about $450 million ( $270 million in cash and $180 million in Tarsus shares). In addition, up to $350 million in contingent payments are planned upon approval and first commercialization, along with degressively tiered royalties in the low single-digit percentage range. The acquisition target is gildeuretinol (ALK‑001), a once‑daily oral Phase 3 candidate for the treatment of Stargardt disease that has received FDA designations such as Breakthrough and Orphan Drug. The ongoing NORTHSTAR study is expected to enroll around 230 patients; initial results are anticipated in the second half of 2029. Closing is targeted for 2026 and remains subject to regulatory approvals; the Tarsus shares to be issued were valued at $61.38 per share. » Plus sur de.investing.com

Tarsus Pharmaceuticals has acquired iRenix Medical and is paying about $75 million upfront, split into $37.5 million in cash and $37.5 million in common stock. Additional milestone payments for approval and commercialization could total up to $490 million. IRX-101, an ocular antiseptic to reduce postprocedural pain and corneal toxicity from intravitreal injections, showed significant improvements versus povidone-iodine in a phase-2b/3 study. Tarsus plans to start a phase-3 trial based on FDA feedback, with recruitment scheduled for H1 2027; the company reportedly has a strong balance sheet and the stock has recently risen sharply. » Plus sur de.investing.com